Occlude Defect ,
To provide global doctors and patients with safe and innovate medical devices to treat cardiovascular diseases
Being an innovative company, we consistently explore new idea and methods
On the afternoon of October 12, 2018, during the 18th National Academic Conference on Thoracic and Cardiovascular Surgery of the Chinese Medical Association (CMA), Lifetech held a seminar entitled "focus on treatment of aortic arch diseases, application of Ankura? stent in aortic endovascular repair"
Recently, the annual CSI AFRICA 2018 was held in Cairo, Egypt. Lifetech was invited to participate in this academic event, where it showed the industry its strong innovation strength.
Guangzhou, China – On October 23rd, the first global press release of the Lifetech Absnow? biodegradable Atrial Septal Defect closure system was held at the Guangdong Cardiovascular Institute, Guangdong General Hospital, gathering representatives from multiple media around China.
LifeTech Scientific Corporation announced that it had entered into the Agreement with the wholly-owned subsidiary of China Everbright Limited, agreed to purchase, with funding to be provided by the Company, and the Vendor conditionally agreed to sell, an aggregate of not more than 300,000,000 shares, for the purpose of the Share Award Scheme.
On the afternoon of December 20, 2018, Jia Xingdong, Director of Shenzhen Municipal Commission of Economic Trade and Information Technology, and his delegation visited Lifetech for investigation
In 2018, Lifetech was approved to obtain two key national R&D program projects.
Lifetech is a leading developer, manufacturer and vendor of advanced minimally invasive medical devices for cardiovascular and peripheral vascular diseases and disorders.
Founded in 1999, we are now the second largest provider of congenital heart defect occluders in the world and the largest provider to BRIC countries.